gastroparesis from semaglutide Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient Clinician Insights on How to

Funding This work and associated article processing charges were supported by Eli Lilly and Company

Work with your healthcare provider to compile baseline labs (BMI, vital signs, comorbid diagnoses, HbA1c if diabetic) and any prior weight-loss attemptswritten documentation strengthens prior authorization requests and speeds approval timelines

As litigation unfolds and regulatory clarity emerges, stakeholders will need to stay informed and adaptable to responsibly meet patient needs in this rapidly changing therapeutic space

Other Double Agonists and Triple Agonist Beyond tirzepatide, pharmaceutical companies have developed additional dual receptor agonists targeting GLP-1 and glucagon (GCG) as well as triple receptor agonists.210 Mazdutide represents the most recent advancement in GLP-1/GCG dual receptor agonists;211213 this agent, co-developed by Cinda Biology and Lilly Pharmaceutical, received marketing approval in China on June 27, 2025

Nations with high rates of obesity could deploy it to reduce their risk of related illnesses

How long do I need to take GLP-1 therapy